{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:28:50Z","timestamp":1781900930307,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ50163"],"award-info":[{"award-number":["2022JJ50163"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific research Fund of hunan provincial education department","award":["19A418"],"award-info":[{"award-number":["19A418"]}]},{"name":"Scientific Research Fund Project of Hunan Provinci al Health Commission","award":["20201973"],"award-info":[{"award-number":["20201973"]}]},{"name":"Central government funds for guiding local scientific and Technological Development","award":["2021QZY016"],"award-info":[{"award-number":["2021QZY016"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823"],"award-info":[{"award-number":["2020SK51823"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11033-023-08836-0","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:02:41Z","timestamp":1697036561000},"page":"9637-9647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response"],"prefix":"10.1007","volume":"50","author":[{"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"issue":"1","key":"8836_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","volume":"9","author":"N Marx","year":"2021","unstructured":"Marx N, Davies MJ, Grant PJ et al (2021) Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 9(1):46\u201352","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"8836_CR2","doi-asserted-by":"publisher","first-page":"e142243","DOI":"10.1172\/JCI142243","volume":"131","author":"SI Taylor","year":"2021","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL (2021) Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest 131(2):e142243","journal-title":"J Clin Invest"},{"issue":"2","key":"8836_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cpt.1484","volume":"106","author":"ER Pearson","year":"2019","unstructured":"Pearson ER, Diabetes (2019) Is there a future for pharmacogenomics guided treatment? Clin Pharmacol Ther 106(2):329\u2013337","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"8836_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","volume":"64","author":"W Rathmann","year":"2021","unstructured":"Rathmann W, Bongaerts B (2021) Pharmacogenetics of novel glucose-lowering drugs. Diabetologia 64(6):1201\u20131212","journal-title":"Diabetologia"},{"issue":"1","key":"8836_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5(1):133\u2013141","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"8836_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2217\/pgs.13.61","volume":"14","author":"A T\u00f6njes","year":"2013","unstructured":"T\u00f6njes A, Kovacs P (2013) SGLT2: a potential target for the pharmacogenetics of type 2 diabetes? Pharmacogenomics 14(7):825\u2013833","journal-title":"Pharmacogenomics"},{"issue":"1","key":"8836_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-019-0929-7","volume":"18","author":"B Fishman","year":"2019","unstructured":"Fishman B, Shlomai G, Twig G et al (2019) Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. Cardiovasc Diabetol 18(1):124","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"8836_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","volume":"447","author":"EM Wright","year":"2004","unstructured":"Wright EM, Turk E (2004) The sodium\/glucose cotransport family SLC5. Pflugers Arch 447(5):510\u2013518","journal-title":"Pflugers Arch"},{"issue":"1","key":"8836_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1523-1755.2005.00053.x","volume":"67","author":"D Magen","year":"2005","unstructured":"Magen D, Sprecher E, Zelikovic I, Skorecki K (2005) A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67(1):34\u201341","journal-title":"Kidney Int"},{"issue":"3","key":"8836_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00439-003-1054-x","volume":"114","author":"J Calado","year":"2004","unstructured":"Calado J, Soto K, Clemente C, Correia P, Rueff J (2004) Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 114(3):314\u2013316","journal-title":"Hum Genet"},{"issue":"5","key":"8836_CR11","first-page":"4364","volume":"19","author":"S Li","year":"2019","unstructured":"Li S, Yang Y, Huang L, Kong M, Yang Z (2019) A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a chinese family, and a review of the relevant literature. Mol Med Rep 19(5):4364\u20134376","journal-title":"Mol Med Rep"},{"issue":"2","key":"8836_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y (2020) SGLT2 inhibitors: the Star in the treatment of type 2 diabetes? Diseases 8(2):14","journal-title":"Diseases"},{"key":"8836_CR13","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R (2021) Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 8:777861","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"8836_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00125-019-4909-y","volume":"62","author":"ER Pearson","year":"2019","unstructured":"Pearson ER (2019) Type 2 diabetes: a multifaceted disease. Diabetologia 62(7):1107\u20131112","journal-title":"Diabetologia"},{"issue":"5","key":"8836_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00125-017-4210-x","volume":"60","author":"MI McCarthy","year":"2017","unstructured":"McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793\u2013799","journal-title":"Diabetologia"},{"issue":"1","key":"8836_CR16","doi-asserted-by":"publisher","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright EM (2001) Renal na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280(1):F10\u2013F18","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3 Pt 2","key":"8836_CR17","first-page":"F459","volume":"263","author":"RG Wells","year":"1992","unstructured":"Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263(3 Pt 2):F459\u2013F465","journal-title":"Am J Physiol"},{"issue":"49","key":"8836_CR18","doi-asserted-by":"publisher","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","volume":"270","author":"G You","year":"1995","unstructured":"You G, Lee WS, Barros EJ et al (1995) Molecular characteristics of na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270(49):29365\u201329371","journal-title":"J Biol Chem"},{"issue":"1","key":"8836_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13(1):11\u201326","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"8836_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12(2):78\u201389","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"8836_CR21","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M et al (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306(2):F188\u2013F193","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"8836_CR22","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi C, Loo DDF, Wright EM (2018) Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 61(10):2087\u20132097","journal-title":"Diabetologia"},{"key":"8836_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","volume":"170","author":"H Koepsell","year":"2017","unstructured":"Koepsell H (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 170:148\u2013165","journal-title":"Pharmacol Ther"},{"issue":"8","key":"8836_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","volume":"92","author":"N Ishikawa","year":"2001","unstructured":"Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N (2001) SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92(8):874\u2013879","journal-title":"Jpn J Cancer Res"},{"issue":"30","key":"8836_CR25","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112(30):E4111\u2013E4119","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8836_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22(1):104\u2013112","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"8836_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00441-020-03358-8","volume":"384","author":"CB Hughes","year":"2021","unstructured":"Hughes CB, Mussman GM, Ray P et al (2021) Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis. Cell Tissue Res 384(2):527\u2013543","journal-title":"Cell Tissue Res"},{"issue":"5","key":"8836_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/jdi.13417","volume":"12","author":"K Monobe","year":"2021","unstructured":"Monobe K, Noso S, Babaya N et al (2021) Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus. J Diabetes Investig 12(5):728\u2013737","journal-title":"J Diabetes Investig"},{"issue":"11","key":"8836_CR29","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","volume":"14","author":"R Santer","year":"2003","unstructured":"Santer R, Kinner M, Lassen CL et al (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14(11):2873\u20132882","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"8836_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000381677","volume":"129","author":"I Aires","year":"2015","unstructured":"Aires I, Fila M, Polidori D, Santos AR, Costa AB, Calado J (2015) Determination of the renal threshold for glucose excretion in familial renal glucosuria. Nephron 129(4):300\u2013304","journal-title":"Nephron"},{"issue":"3","key":"8836_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00439-010-0927-z","volume":"129","author":"L Yu","year":"2011","unstructured":"Yu L, Lv JC, Zhou XJ, Zhu L, Hou P, Zhang H (2011) Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum Genet 129(3):335\u2013344","journal-title":"Hum Genet"},{"issue":"8","key":"8836_CR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/1753-0407.13183","volume":"13","author":"DT Papadimitriou","year":"2021","unstructured":"Papadimitriou DT, Manolakos E, Dermitzaki E et al (2021) A novel heterozygous mutation in the SLC5A2 gene causing severe glycosuria, mild failure to thrive, and subclinical hypoglycemia. J Diabetes 13(8):688\u2013692","journal-title":"J Diabetes"},{"issue":"1","key":"8836_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-020-01725-9","volume":"21","author":"L Yu","year":"2020","unstructured":"Yu L, Wu M, Hou P, Zhang H (2020) SLC5A2 mutations, including two novel mutations, responsible for renal glucosuria in chinese families. BMC Nephrol 21(1):69","journal-title":"BMC Nephrol"},{"key":"8836_CR34","doi-asserted-by":"publisher","first-page":"996946","DOI":"10.3389\/fped.2022.996946","volume":"10","author":"H Huang","year":"2022","unstructured":"Huang H, Wu X, He Q et al (2022) Case report: identification of three novel compound heterozygous SGLT2 variants in three chinese pediatric patients with familial renal glucosuria. Front Pediatr 10:996946","journal-title":"Front Pediatr"},{"key":"8836_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cca.2018.12.024","volume":"490","author":"S Wang","year":"2019","unstructured":"Wang S, Zhao X, Zhang R, Wang C, Han Y, Shao L (2019) Identification of ten novel SLC5A2 mutations and determination of the renal threshold for glucose excretion in chinese patients with familial renal glucosuria. Clin Chim Acta 490:102\u2013106","journal-title":"Clin Chim Acta"},{"issue":"8","key":"8836_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/pgs.11.69","volume":"12","author":"U Enigk","year":"2011","unstructured":"Enigk U, Breitfeld J, Schleinitz D et al (2011) Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 12(8):1119\u20131126","journal-title":"Pharmacogenomics"},{"issue":"8","key":"8836_CR37","doi-asserted-by":"publisher","first-page":"BSR20190299","DOI":"10.1042\/BSR20190299","volume":"39","author":"H Drexel","year":"2019","unstructured":"Drexel H, Leiherer A, Saely CH et al (2019) Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. Biosci Rep 39(8):BSR20190299","journal-title":"Biosci Rep"},{"issue":"5","key":"8836_CR38","doi-asserted-by":"publisher","first-page":"e0177148","DOI":"10.1371\/journal.pone.0177148","volume":"12","author":"AM Ordelheide","year":"2017","unstructured":"Ordelheide AM, B\u00f6hm A, Kempe-Teufel D et al (2017) Common variation in the sodium\/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS ONE 12(5):e0177148","journal-title":"PLoS ONE"},{"issue":"1","key":"8836_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/cpt.2153","volume":"110","author":"JL Katzmann","year":"2021","unstructured":"Katzmann JL, Mason AM, M\u00e4rz W et al (2021) Genetic variation in Sodium-glucose cotransporter 2 and heart failure. Clin Pharmacol Ther 110(1):149\u2013158","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"8836_CR40","first-page":"276","volume":"39","author":"J Klen","year":"2020","unstructured":"Klen J, Gori\u010dar K, Dol\u017ean V (2020) Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients. J Med Biochem 39(3):276\u2013282","journal-title":"J Med Biochem"},{"issue":"9","key":"8836_CR41","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/jcph.1866","volume":"61","author":"JC Marshall","year":"2021","unstructured":"Marshall JC, Liang Y, Sahasrabudhe V et al (2021) Meta-analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to evaluate dose proportionality and UGT1A9 polymorphism effect on exposure. J Clin Pharmacol 61(9):1220\u20131231","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"8836_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","volume":"55","author":"E Hoeben","year":"2016","unstructured":"Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A (2016) Population Pharmacokinetic modeling of Canagliflozin in healthy volunteers and patients with type 2 diabetes Mellitus. Clin Pharmacokinet 55(2):209\u2013223","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"8836_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/jcph.506","volume":"55","author":"S Francke","year":"2015","unstructured":"Francke S, Mamidi RN, Solanki B et al (2015) In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55(9):1061\u20131072","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"8836_CR44","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1124\/dmd.120.000171","volume":"48","author":"K Lapham","year":"2020","unstructured":"Lapham K, Callegari E, Cianfrogna J et al (2020) In Vitro characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 enzymes. Drug Metab Dispos 48(12):1350\u20131363","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"8836_CR45","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/bcp.15117","volume":"88","author":"MD Naagaard","year":"2022","unstructured":"Naagaard MD, Chang R, N\u00e5g\u00e5rd M, Tang W, Boulton DW (2022) Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. Br J Clin Pharmacol 88(4):1942\u20131946","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"8836_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","volume":"62","author":"T Saito","year":"2015","unstructured":"Saito T, Okada S, Yamada E et al (2015) Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J 62(12):1133\u20131137","journal-title":"Endocr J"},{"issue":"4","key":"8836_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12793\/tcp.2022.30.e23","volume":"30","author":"JG Hwang","year":"2022","unstructured":"Hwang JG, Jeong SI, Kim YK et al (2022) Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol 30(4):212\u2013225","journal-title":"Transl Clin Pharmacol"},{"issue":"4","key":"8836_CR48","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s13300-018-0449-6","volume":"9","author":"MJ Pereira","year":"2018","unstructured":"Pereira MJ, Lundkvist P, Kamble PG et al (2018) A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in individuals with obesity and without diabetes: metabolic Effects and markers Associated with Bodyweight loss. Diabetes Ther 9(4):1511\u20131532","journal-title":"Diabetes Ther"},{"issue":"4","key":"8836_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7(4):313\u2013324","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"8836_CR50","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1074\/jbc.RA118.002333","volume":"293","author":"MA Mitsche","year":"2018","unstructured":"Mitsche MA, Hobbs HH, Cohen JC (2018) Patatin-like phospholipase domain\u2013containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 293(18):6958\u20136968","journal-title":"J Biol Chem"},{"issue":"12","key":"8836_CR51","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461\u20131465","journal-title":"Nat Genet"},{"key":"8836_CR52","first-page":"22","volume":"2022","author":"R Nakajima","year":"2022","unstructured":"Nakajima R, Sekiya M, Furuta Y et al (2022) A case of NASH with genetic predisposition successfully treated with an SGLT2 inhibitor: a possible involvement of mitochondrial dysfunction. Endocrinol Diabetes Metab Case Rep 2022:22\u20130368","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"8836_CR53","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA et al (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9):1923\u20131934","journal-title":"Diabetologia"},{"issue":"4","key":"8836_CR54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/FPC.0000000000000268","volume":"27","author":"H Zimdahl","year":"2017","unstructured":"Zimdahl H, Haupt A, Brendel M et al (2017) Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics 27(4):135\u2013142","journal-title":"Pharmacogenet Genomics"},{"issue":"680","key":"8836_CR55","doi-asserted-by":"publisher","first-page":"eabp9952","DOI":"10.1126\/scitranslmed.abp9952","volume":"15","author":"H Guo","year":"2023","unstructured":"Guo H, Yu X, Liu Y et al (2023) SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med 15(680):eabp9952","journal-title":"Sci Transl Med"},{"issue":"2","key":"8836_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.gene.2013.05.002","volume":"526","author":"H Han","year":"2013","unstructured":"Han H, Wang H, Yin Z, Jiang H, Fang M, Han J (2013) Association of genetic polymorphisms in ADH and ALDH2 with risk of coronary artery disease and myocardial infarction: a meta-analysis. Gene 526(2):134\u2013141","journal-title":"Gene"},{"issue":"6","key":"8836_CR57","doi-asserted-by":"publisher","first-page":"898","DOI":"10.4093\/dmj.2018.0257","volume":"43","author":"YC Hwang","year":"2019","unstructured":"Hwang YC, Kim JH, Lee BW, Lee WJ (2019) A lower baseline urinary glucose excretion predicts a better response to the Sodium glucose cotransporter 2 inhibitor. Diabetes Metab J 43(6):898\u2013905","journal-title":"Diabetes Metab J"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08836-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:18:29Z","timestamp":1707409109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08836-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8836"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08836-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}